Background: The purpose of PARAGON is to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular (CV) death and HF hospitalizations in patients with HF with preserved EF (HFpEF) Trial Registration No: NCT02064868 ( Link Trial Status: Randomized worldwide: 4600, Recruitment stopped Randomized in Basel: 7 Enrolling Centers: Switzerland Worldwide: Basel, Zürich, Bern, Lausanne, 39 in different countries Biel, Lugano Core Study Team:
© Christian Mueller, 2012 - 2024 │ DisclaimerImprintWebmaster │ Last Update: June 2024
Kristin Shrestha Beate Hartmann Ph.D. Eleni Michou Rafal Czmok